Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s
Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations
MoU to deploy Qure.ai’s chest X-ray solution across 20 government facilities aims to improve early detection in urban and rural populations
With more than two decades of experience, he brings deep expertise in sales, marketing, business transformation, and strategic leadership
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
Subscribe To Our Newsletter & Stay Updated
